
Opinion|Videos|July 16, 2024
BTK Inhibitors' Rationale and Potential Role in Multiple Sclerosis Treatment
Heidi Crayton, MD, discusses the rationale for investigating Bruton tyrosine kinase inhibitors (BTKis) as a treatment for patients with multiple sclerosis and the current stage of development for evobrutinib, tolebrutinib, and other BTKis.
Advertisement
Episodes in this series

Video content above is prompted by the following questions:
- What was the rationale for the investigation of Bruton tyrosine kinase inhibitors (BTKis) for use as treatment in patients with multiple sclerosis (MS)?
- What is the stage in development for evobrutinib, tolebrutinib and other BTKis?
- How might these therapies fit into treatment algorithms for different types of MS?
- How do payers see these therapies being integrated into treatment algorithms?
Advertisement
Related to this article

FDA approves dexmedetomidine sublingual film for at-home use in adults with schizophrenia, schizoaffective disorder, or bipolar I or II disorder.

Non-US-born adults had higher CRC screening nonadherence than US-born adults, particularly those with less than 15 years of US residence.

Once weekly ribupatide, a dual GIP/GLP-1 receptor agonist, led to significantly greater weight loss than placebo at 48 weeks, according to a study.

The once weekly self-injected treatment is the first dual-binding nanobody C5 inhibitor approved for adults with AChR antibody-positive gMG.

A TriNetX retrospective cohort found adults with alopecia areata—especially women—face a nearly doubled glaucoma risk, with implications for ophthalmology and comorbidities.

β3 agonists were not linked to lower dementia incidence vs anticholinergics among 830,393 adults treated for overactive bladder, a cohort study found.

Research at ObesityWeek 2026 tracks rising obesity in Medicare, productivity losses, prior authorization denials, and GLP-1 persistence.
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves Dexmedetomidine Sublingual Film as At-Home Agitation Therapy
2
ObesityWeek 2026: Studies Map GLP-1 Access Gaps, Obesity's Costs
3
FDA Approves Weekly Gefurulimab for Generalized Myasthenia Gravis
4
Nondrug Therapies Ease Cough in Lung Cancer, Pulmonary Rehab Leads Pack
5


